AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
GlycoMimetics Inc (NASDAQ:GLYC)
-- USD
0.000 0.000%Sponsored Reports
Loading...
| Previous Close (in USD) | -- |
|---|---|
| Change | 0.000 0.000% |
| 52 W H/L (in USD) | 3.530/0.256 |
| EBITDA (in USD) | -39.122M |
| PE Ratio | -- |
| Volume | -- |
| Diluted Eps TTM | -0.58 |
| Total Assets (in USD) | 45.316M |
|---|---|
| Total Liabilities (in USD) | 6.902M |
| Revenue TTM (in USD) | 0.01M |
| Cash (in USD) | 41.793M |
| Market Cap (in USD) | 17.212 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | 0.075M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
GlycoMimetics Inc
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
9708 Medical Center Drive, Rockville, MD, United States, 20850
240 243 1201
Employees: 35
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Harout Semerjian | CEO, Pres & Director | 1970 |
| 2. | Mr. Brian M. Hahn | Sr. VP & CFO | 1974 |
| 3. | Dr. John L. Magnani Ph.D. | Sr. VP of Research & Chief Scientific Officer | 1953 |
| 4. | Ms. Stephanie R. Irish CPA | VP of Accounting | 1971 |
| 5. | Mr. Christian Dinneen-Long | VP, Corp. Counsel & Corp. Sec. | NA |
| 6. | Mr. Armand Girard | Chief Bus. Officer and Sr. VP of Strategy & Corp. Devel. | 1969 |
| 7. | Mr. Bruce Johnson | Sr. VP & Chief Commercial Officer | NA |
| 8. | Dr. Edwin Rock M.D., Ph.D. | Chief Medical Officer | NA |
| 9. | Mr. Harout Semerjian | CEO, President & Director | 1970 |
| 10. | Ms. Rachel K. King | Co-Founder & Director | 1959 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.190 0.275% | 69.36 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.090 0.130% | 69.4 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-0.080 0.017% | 460 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-10.705 1.956% | 546 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -46.688M | -63.427M | -51.027M | -57.892M | -48.274M |
| Minority Interest | - | - | - | - | - |
| Net Income | -93.329M | -63.142M | -50.274M | -54.116M | -48.274M |
| Selling General Administrative | 19.087M | 17.115M | 16.743M | 14.36M | 11.413M |
| Gross Profit | 0.075M | 1.16M | 10.163M | - | 0M |
| Reconciled Depreciation | 0.207M | 0.265M | 0.271M | 0.279M | 0.275M |
| Ebit | -47.61M | -63.712M | -51.78M | -61.668M | -51.78M |
| Ebitda | -47.403M | -63.447M | -51.509M | -61.389M | -51.505M |
| Depreciation And Amortization | 0.207M | 0.265M | 0.271M | 0.279M | 0.275M |
| Operating Income | -47.403M | -63.447M | -51.509M | -61.389M | -51.505M |
| Other Operating Expenses | 47.478M | 64.607M | 61.672M | 61.389M | 51.505M |
| Interest Expense | 46.641M | 0.02M | 0M | 0M | 0M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 0.715M | 0.02M | 0.482M | 3.497M | 3.231M |
| Net Interest Income | 0.715M | 0.02M | 0.482M | 3.497M | 3.231M |
| Income Tax Expense | 46.641M | -0.285M | -0.753M | -3.776M | 3.231M |
| Total Revenue | 0.075M | 1.16M | 10.163M | 0M | 0M |
| Total Operating Expenses | 47.478M | 64.607M | 61.672M | 61.389M | 51.505M |
| Cost Of Revenue | - | - | - | - | 0M |
| Total Other Income Expense Net | 0.715M | 0.02M | 0.482M | 3.497M | 3.231M |
| Net Income From Continuing Ops | -46.688M | -63.427M | -51.027M | -57.892M | -48.274M |
| Net Income Applicable To Common Shares | -46.689M | -63.427M | -51.027M | -57.892M | -48.274M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 45.316M | 51.811M | 94.347M | 142.832M | 167.97M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 1.822M | 2.844M | 533.804M | 1238.328M | 4326.322M |
| Total Liab | 6.902M | 8.881M | 12.743M | 14.613M | 13.769M |
| Total Stockholder Equity | 38.414M | 42.93M | 81.604M | 128.219M | 154.201M |
| Other Current Liab | 5.226M | 6.992M | 8.715M | 9.44M | 8.711M |
| Common Stock | 0.064M | 0.054M | 0.052M | 0.049M | 0.043M |
| Capital Stock | 0.064M | 0.054M | 0.052M | 0.049M | 0.043M |
| Retained Earnings | -456.485M | -419.586M | -372.897M | -309.47M | -258.443M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | 0M | 1.613M | -0M | 0M |
| Cash | 41.793M | 47.871M | 90.255M | 137.035M | 158.201M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 6.835M | 8.881M | 11.824M | 12.428M | 10.951M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | -40.984M | -46.952M | -88.335M | -134.216M | -154.578M |
| Short Term Debt | 0.742M | 0.919M | 1.001M | 0.899M | 0.804M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 0.808M | 0.919M | 1.92M | 2.819M | 3.623M |
| Other Stockholder Equity | 494.835M | 462.461M | 454.449M | 437.64M | 412.6M |
| Property Plant Equipment | - | 0.994M | 1.945M | 0.621M | 0.823M |
| Total Current Assets | 43.791M | 50.715M | 90.255M | 138.273M | 162.528M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 0.176M | 0.144M | 0.001M | 0.002M | 0.186M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | -0.144M | -533.805M | -1237.092M | -4322.181M |
| Accounts Payable | 0.868M | 0.97M | 2.108M | 2.09M | 1.436M |
| Accumulated Other Comprehensive Income | - | - | - | - | -1.862M |
| Non Currrent Assets Other | 0.758M | 0.102M | 2.147M | 1.613M | 1.613M |
| Non Current Assets Total | 1.526M | 1.096M | 4.092M | 4.559M | 5.442M |
| Capital Lease Obligations | 0.808M | 0.919M | 1.92M | 2.819M | 3.623M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -0.084M | -0.015M | -0.069M | -0.145M | -0.126M |
| Total Cashflows From Investing Activities | -0.084M | -0.015M | -0.069M | -0.145M | -0.126M |
| Total Cash From Financing Activities | 4.157M | 10.724M | 18.144M | 0.413M | 129.45M |
| Net Income | -46.689M | -63.427M | -51.027M | -57.892M | -48.274M |
| Change In Cash | -42.384M | -46.78M | -21.166M | -51.716M | 85.993M |
| Begin Period Cash Flow | 90.255M | 137.035M | 158.201M | 209.918M | 123.925M |
| End Period Cash Flow | 47.871M | 90.255M | 137.035M | 158.201M | 209.918M |
| Total Cash From Operating Activities | -46.457M | -57.49M | -39.242M | -51.984M | -43.331M |
| Depreciation | 0.207M | 0.265M | 0.271M | 0.279M | 0.275M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | - | - | 18.144M | 0.413M | 129.45M |
| Other Cashflows From Financing Activities | -0.084M | 0.025M | 0.319M | 0.413M | 1.025M |
| Capital Expenditures | 0.084M | 0.015M | 0.069M | 0.145M | 0.126M |
| Change In Working Capital | -4.662M | -1.165M | 3.932M | -1.207M | 0.08M |
| Other Non Cash Items | 0.829M | 0.749M | 0.681M | 0.62M | 0M |
| Free Cash Flow | -46.542M | -57.504M | -39.31M | -52.129M | -43.457M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 1925297 |
| 2. | UTM IM GBP AXA Framlington Biotech | 1 year ago | 1522096 |
| 3. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 730599 |
| 4. | Fidelity Extended Market Index | 1 year ago | 268558 |
| 5. | Bridgeway Ultra-Small Company Market | 1 year ago | 163200 |
| 6. | BlackRock Extended Mkt Composite | 1 year ago | 122969 |
| 7. | iShares Micro-Cap ETF | 1 year ago | 114517 |
| 8. | BlackRock Extended Equity Market K | 1 year ago | 107319 |
| 9. | Fidelity Total Market Index | 1 year ago | 80838 |
| 10. | AXA IM Wave Biotech A Cap USD | 1 year ago | 65645 |
| 11. | Avantis US Small Cap Equity ETF | 1 year ago | 65066 |
| 12. | Fidelity Series Total Market Index | 1 year ago | 64457 |
| 13. | A&P Lifescience Fund A FI | 1 year ago | 59583 |
| 14. | Vanguard Balanced Index Inv | 1 year ago | 54900 |
| 15. | NT Ext Equity Mkt Idx Fd - NL | 1 year ago | 51980 |
| 16. | RIM Global Bioscience EUR | 1 year ago | 46000 |
| 17. | Northern Trust Extended Eq Market Idx | 1 year ago | 42348 |
| 18. | NT Ext Equity Mkt Idx Fd - L | 1 year ago | 42348 |
| 19. | Vanguard Instl Ttl Stk Mkt Idx InstlPls | 1 year ago | 36873 |
| 20. | Vanguard Instl Ttl Stck Mkt Idx Tr | 1 year ago | 36873 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Bvf Inc | 1 year ago | 9544262 |
| 2. | Artal Group S A | 1 year ago | 8589064 |
| 3. | NEA Management Company, LLC | 1 year ago | 3835039 |
| 4. | Octagon Capital Advisors LP | 1 year ago | 3000000 |
| 5. | Vanguard Group Inc | 1 year ago | 2761981 |
| 6. | Goldman Sachs Group Inc | 1 year ago | 1838710 |
| 7. | AXA SA | 1 year ago | 1587741 |
| 8. | Millennium Management LLC | 1 year ago | 746954 |
| 9. | BlackRock Inc | 1 year ago | 734983 |
| 10. | Geode Capital Management, LLC | 1 year ago | 478883 |
| 11. | Acadian Asset Management LLC | 1 year ago | 330526 |
| 12. | Marshall Wace Asset Management Ltd | 1 year ago | 217501 |
| 13. | State Street Corporation | 1 year ago | 186765 |
| 14. | Bridgeway Capital Management, LLC | 1 year ago | 168600 |
| 15. | Verition Fund Managegment, LLC | 1 year ago | 162428 |
| 16. | Man Group PLC | 1 year ago | 149859 |
| 17. | Connor Clark & Lunn Inv Mgmt Ltd | 1 year ago | 143359 |
| 18. | Citigroup Inc | 1 year ago | 137667 |
| 19. | Renaissance Technologies Corp | 1 year ago | 124444 |
| 20. | Susquehanna International Group, LLP | 1 year ago | 111491 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...